Microsaic Systems Share Discussion Threads

[daar] 27/9/2021 09:42

Going going going gone!!

[janhar] 27/9/2021 07:05

Results out

[mrscocker] 24/9/2021 14:49

You might need to explain that to him in more detail I think. Although to be fair there is an awful of cheap stock on this and it has been sold down daily for months and months by profit taking placees.

[david gruen] 24/9/2021 14:40

Shares in issue makes no difference. It's the cap that matters.

[david gruen] 24/9/2021 07:12

Microsaic Systems plc

24 September 2021

24 September 2021

Microsaic Systems plc

("Microsaic" or the "Company")

Microsaic sign manufacturing, supply, and service agreement to support China operations

Production assembly to commence this year and on track for China medical device licence in 2022

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments and solutions, is pleased to announce it has signed an agreement with Jiangsu Henzhihe Technologies Co. Ltd. ("HZH"), to support the Company's relationship with the Chinese distributor (the "Distributor"), with whom the Company announced a signed Heads of Terms for its micro-engineered MS technology (per the RNS dated 4 May 2021). Under the agreement ("Agreement"), HZH will provide integration and service support for Microsaic's operations in China.

HZH will act as the manufacturer, integrator, and service centre in support of distribution and prospective OEM partnerships in China. HZH is a recently incorporated entity whose directors have a long history of working with MS in China and manufacturing other analytical devices, and in active pharmaceutical ingredients ("API"). Their relationships include large analytical instrumentation and pharmaceutical companies. HZH and Microsaic will collaborate with distribution partners to access and service other substantial growth opportunities in the Chinese market.

Production in China of the MS hospital diagnostic monitoring equipment is expected to commence before the end of this year to support the Chinese Distributor through local production and service support, which are pre-requisites to securing a medical license . The Agreement establishes a local presence for Microsaic, accelerating the Company's growth opportunity in China. With an addressable market of 33,000 hospitals having 7.9 million beds(1) , having the ability to scale local production for MS therapeutic drug monitoring ("TDM") and maintain supply and service capability is essential.

Multiple revenue streams are expected in due course, consisting of the sale of MS TDM units, franchise services and sales of reagents, in-line with Microsaic's business strategy.

Once the medical license in China has been secured in 2022, HZH and the Company estimate a target rising to 100 units per annum for each therapeutic drug monitoring sector over the next two to three years, and there several sectors in this market and in other analytical sectors. HZH has confirmed it can meet the prospective demand requirements of Microsaic for China and the rest of the world.

Glenn Tracey, CEO of Microsaic Systems plc, commented:

"With the Company on track to secure a China medical device licence in 2022, developing the capability with local partners for mass production of Microsaic equipment in China represents a significant opportunity to reduce costs and increase available margins for these devices. This demonstrates our commitment to position our point-of-need technology in a broad range of key verticals within the human health diagnostics sector.

"With a focus on commercialisation of sample-to-result platforms, and equipment with network management software capability (and later artificial intelligence ("AI") software, we look forward to providing further updates on production and distribution to the market as they arise ."

Abbin Huang, MD of HZH, commented:

"The Microsaic miniaturised mass spectrometers are unique and of great interest for a range of markets in China. We particularly see great potential in clinical and bioprocessing applications where real-time, point - of - need data is extremely valuable. We look forward to a long-term and close collaboration with Microsaic to serve the needs of the Chinese market ."

(1) China Hospital Industry Report, 2019-2025

[hodhasharen] 01/9/2021 23:58

Sorry who you talking about

[daveboy19] 01/9/2021 08:36

Yep, seen similar on another board, where a guy called some dodgy traders out for underhand tactics, and now they follow him around incessantly trying to blacken his name, when all the time it is they who are up to no good. They also copy usernames and band together like hyenas. Disgusting.

[david gruen] 01/9/2021 08:29

Please don't mistake hodhasharen for the real Hoddles (the one with the long standing paid account who created this thread).

hodhasharen is Peaky Trader. He claimed for months to be topping up on SYME. Claimed to have 122 Million Shares. He posted a screenshot.

Guess what!

He had 1.22 Million. We laughed at him and he's taking some kind of revenge.

[daveboy19] 01/9/2021 08:24

Give me strength.

[hodhasharen] 01/9/2021 07:28

Heading south very fast. 0.0001p today.In TW we trust and prosper.

[mrscocker] 31/8/2021 09:46

Another Zak Mir "tip" and guess what, the share price drops.Happens every time he says it will rise, it falls.Just saying.

[mrscocker] 27/8/2021 15:29

Absolutely Ragnarr, could be very special here and elsewhere..and about time too

[ragnarr] 27/8/2021 15:09

Roll on September Mrs C

[mrscocker] 27/8/2021 13:42

is that the bottom finally being called here?

[mrscocker] 24/8/2021 14:51

As Gbenson highlights it's been trading in a fairly well defined range between 0.2 and 0.25 for the last 6 months without contract news and with all those endless large volume sells almost very day. I would be surprised to see it go lower from here but then no one really can call the absolute bottom on any stock these days. I am happy to take my chances from here even if I miss the bottom by 10 or 20%.

[onehanded] 24/8/2021 14:36

Did see that, but would have seen a massive churn from Feb time and would not expect to much to go and with a lot of news and the China manufacturing news, can only see it being a boost in the coming few months. BUT who knows, not bought yet.

[gbenson1] 24/8/2021 14:14

Be very careful here, TP received circa 1.5bn shares or options @ 0.010p, they have been selling from 0.026 down to 0.018, don't think the share price will go as low as 0.010p however there may still be some more downside before a bottom is reached, imho

[onehanded] 24/8/2021 13:49

Have NO investment here with MSYS, but today doing some research to see if I should. Fully invested in Deepverge. GB did confirm yesterday that MSYS is fully funded this year , which was one of my concerns of a placing soon. With that out of the way seems more attractive.

Found a few good things..

MSYS is debt free

Short Term Liabilities: MSYS's short term assets (£1.4M) exceed its short term liabilities (£238.3K).

Long Term Liabilities: MSYS's short term assets (£1.4M) exceed its long term liabilities (£125.1K)

Could be worth a small investment here.

[ragnarr] 23/8/2021 11:15

Interesting article re EU drive to eradicate substances of very high concern worth a read for investors.https://www.irishtimes.com/news/science/will-the-new-eu-chemicals-strategy-make-our-world-less-toxic-1.4527407

[ragnarr] 23/8/2021 10:03

The European Commission has revised certain information requirements for registering chemicals under REACH. The changes will start to apply in early 2022 and companies need to start preparing. ECHA will publish more advice in late 2021.https://echa.europa.eu/-/upcoming-changes-to-reach-information-requirements